Enter a keyword or phrase to search all pages in this section:

Advanced search


Looking for a previously published document in this section?

Drug safety information: Dekristol (20,000 IU Colecalciferol) Capsules - EL (12)A/03

Document details:

Type: Drug Alert
Series No: EL (12)A/03
Audience: Healthcare professional
Published: 23 January 2012 14:00
Format: Electronic
Size: A4
Pages: 1
Price: Free
Copyright: Crown

Help viewing PDFs:


Drug safety information

For immediate dissemination during working hours.

23 January 2012 EL (12)A/03 Our ref: 

MDR 39-01/12

Dear Healthcare Professional,

MIBE GMBH, Germany

MHRA Safety Information for Dekristol (20,000 IU Colecalciferol) Capsules

The above unlicensed product is imported in significant quantities into the UK.

Importers of medicines that are unlicensed in the UK must notify the MHRA in accordance with The Medicines for Human Use (Manufacturing, Wholesale Dealing and Miscellaneous Amendments) Regulations 2005/2789 (external link). For further information, please see also Guidance Note 14 PDF file (opens in new window).

Notifications for importation of unlicensed medicines are assessed by the MHRA and objections may be raised where there are prohibitive safety or quality concerns, or in the case of non-objections to import, advice issued where users need to be aware of safety or quality issues.

Although importers are advised that the prescriber must be made aware that Dekristol capsules contain arachis (peanut) oil, and are contraindicated for patients with nut allergies, it has come to the attention of the MHRA that not all users may be aware of these safety issues. This is of particular concern because packs and leaflets are in the German language. Although there is currently no legal requirement for imported medicines to be labelled in English, the expectation in the National Health Service (NHS) is that suitable English language labelling will be provided as a matter of good practice. NHS guidance has been issued which reflects this.

Allergy to arachis oil may lead to severe allergic reactions including anaphylaxis. Recipients are therefore asked to bring this information to the attention of relevant professionals.

Yours faithfully,

Graham Matthews
Senior Pharmaceutical Assessor, Unlicensed Medicines

MHRA Distribution (further recipients by cascade):

Regional contacts for NHS trusts and provider units
Chief pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special hospitals
Care Quality Commission for distribution to Independent health care establishments
Primary care trusts (England)
Page last modified: 23 January 2012